Ares Life Sciences acquires 45.86% stake in Stallergenes
Plans mandatory takeover offer for all remaining outstanding shares
Swiss healthcare investment firm Ares Life Sciences has acquired 45.86% of the share capital and voting rights of Stallergenes at a price of €59.00 per share.
Stallergenes is one of Europe's leading biopharmaceutical companies and a world leader in sublingual immunotherapy. Ares Life Sciences will seek to work with Stallergenes' management to ensure the company's continued success and accelerate its development.
‘Ares Life Sciences is a long-term investor in health care companies. We are delighted to be a major shareholder in Stallergenes, a leader in the allergy treatment market with strong fundamentals, proven technology and an experienced management team,’ said Jacques Theurillat, ceo of Ares Life Sciences.
‘As Stallergenes prepares to launch new products and enter new markets, we believe that Ares Life Science's expertise will provide the support needed to help the company realise its full potential in the future.’
In compliance with the Autorite des Marches Financiers (AMF) regulation, Ares Life Sciences will file a mandatory tender offer for all the remaining outstanding shares of Stallergenes, at the same price of €59.00 per share in cash.
